{
    "organizations": [],
    "uuid": "1c02bf92f3a263d37e5aebbff6944b3fd80534b4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-takara-bio-signs-agreement-for-co/brief-takara-bio-signs-agreement-for-co-development-and-sales-rights-in-japan-to-ny-eso-1-sitcrtm-and-cd19-car-gene-therapies-idUSL3N1RM1VK",
    "ord_in_thread": 0,
    "title": "BRIEF-Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9(Reuters) - Takara Bio Inc\n* Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takaraâ€™s NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies\nSource text in Japanese: goo.gl/YzGkkU\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-04-09T14:39:00.000+03:00",
    "crawled": "2018-04-10T13:04:30.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "takara",
        "bio",
        "inc",
        "say",
        "entered",
        "agreement",
        "otsuka",
        "pharmaceutical",
        "ltd",
        "exclusive",
        "sale",
        "right",
        "japan",
        "takara",
        "sitcrtm",
        "cd19",
        "car",
        "gene",
        "therapy",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}